Thelansis

  Erectile Dysfunction (ED) Market Outlook Thelansis’s “Erectile Dysfunction (ED) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Erectile Dysfunction (ED) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Erectile Dysfunction (ED) Overview Erectile Dysfunction (ED) refers to the recurrent and persistent inability, either partial or complete, to achieve or maintain an erection firm enough for satisfactory sexual intercourse, even when proper erotic stimuli are present. This condition is recognized as a social problem affecting men of various age groups and ethnicities, significantly impacting the quality of life (QoL) for the aff...

Congenital Hemolytic Anemias (CHAs) Market Outlook Thelansis’s “Congenital Hemolytic Anemias (CHAs) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Congenital Hemolytic Anemias (CHAs) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Congenital Hemolytic Anemias (CHAs) Overview Congenital hemolytic anemias (CHAs) refer to a group of rare inherited disorders that manifest as a range of conditions, including defects in erythrocyte membrane proteins, red cell enzymes, and disorders related to defective erythropoiesis. CHAs are characterized by anemia of varying severity, chronic extravascular hemolysis, reduced erythrocyte lifespan,...

  Primary Lateral Sclerosis (PLS) Market Outlook Thelansis’s “Primary Lateral Sclerosis (PLS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Lateral Sclerosis (PLS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Primary Lateral Sclerosis (PLS) Overview Primary lateral sclerosis (PLS) is a rare and poorly understood motor neuron disease characterized by progressive dysfunction of the upper motor neurons, resulting in spasticity, mild weakness in voluntary muscle movements, hyperreflexia, and difficulty with motor speech production. The exact cause of PLS remains unknown, and it comprises less than 4% of all cases of mo...

  Malaria Market Outlook Thelansis’s “Malaria Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Malaria treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Malaria Overview Malaria is an acute febrile illness that arises from the transmission of Plasmodium parasites through the bites of infected female Anopheles mosquitoes. In humans, five parasite species are capable of causing malaria, with P. falciparum and P. vivax posing the most significant risk. P. falciparum is Africa’s most prevalent and deadliest parasite species, while P. vivax dominates in most countries outside of sub-Saharan Africa. The onset of malaria symptoms, which ...

  Ocular Myasthenia Gravis (OMG) Market Outlook Thelansis’s “Ocular Myasthenia Gravis (OMG) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Ocular Myasthenia Gravis (OMG) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Ocular Myasthenia Gravis (OMG) Overview Ocular myasthenia gravis (OMG) is an autoimmune disorder characterized by weakness of the extraocular eye muscles, levator palpebrae superioris, and orbicularis oculi, resulting in ptosis and diplopia. It primarily affects the ocular muscles without involving other muscle groups. Ocular manifestations are common in myasthenia gravis, occurring in 15-50% of cases, with fluct...

  Refractory Generalised Myasthenia Gravis (gMG) Market Outlook Thelansis’s “Refractory Generalised Myasthenia Gravis (gMG) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Refractory Generalised Myasthenia Gravis (gMG) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Refractory Generalised Myasthenia Gravis (gMG) Overview Myasthenia gravis (MG) is a clinically heterogeneous autoimmune disorder affecting the neuromuscular junction. It is characterized by fatigable weakness of voluntary muscles. The onset of MG can occur at any age, but in the adult-onset form, there is a bimodal peak. Generalized MG, which commonly affects women ...

  Oral Cancer Market Outlook Thelansis’s “Oral Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Oral Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Oral Cancer Overview Oral cancer (mouth cancer) is commonly referred to as head and neck cancer. According to WHO, oral cancer is a tumor in the buccal mucosa, the anterior two-thirds of the tongue, the lip, palate, vestibule, alveolus, the floor of the mouth, and gingivae. The most common symptoms of oral cancer include ulceration, induration and rupture, enlarged lesion, inflexible movement of the tongue, and difficulty in speaking and swallowing. Multifactorial etio...

  Generalized Myasthenia Gravis (gMG) Market Outlook Thelansis’s “Generalized Myasthenia Gravis (gMG) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Generalized Myasthenia Gravis (gMG) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Generalized Myasthenia Gravis (gMG) Overview Generalized myasthenia gravis (gMG) is a chronic autoimmune neuromuscular disorder characterized by fluctuating skeletal muscle weakness that worsens with activity and improves with rest. It arises from autoantibodies—most commonly against the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK)—that disrupt normal neuromuscular transmission at...

Influenza A Market Outlook Thelansis’s “Influenza A Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Influenza A treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Influenza A Overview Influenza A virus belongs to the  Orthomyxoviridae  family and is distinguished by its enveloped morphology and segmented, negative-sense, single-stranded RNA genome. The genome comprises eight RNA segments that encode at least 11 proteins, including hemagglutinin (HA), neuraminidase (NA), matrix proteins M1 and M2, nucleoprotein (NP), non-structural proteins NS1 and NS2 (also known as nuclear export protein, NEP), polymerase acidic protein (PA),...

  Influenza B Market Outlook Thelansis’s “Influenza B Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Influenza B treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Influenza B Overview Influenza B is a prevalent respiratory infection. Approximately 20-30% of diagnosed cases of influenza viral infections can be attributed to the influenza B virus. Similar to the influenza A virus, the influenza B virus belongs to the family Orthomyxoviridae. Both viruses possess segments 1, 3, 4, and 5, denoted as FLUA and FLUB, which encode a single protein per segment: PB2, PA, HA, and NP proteins. However, there are a few notable distinctions i...

Traumatic Brain Injury (TBI) Market Outlook Thelansis’s “Traumatic Brain Injury (TBI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Traumatic Brain Injury (TBI) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Traumatic Brain Injury (TBI) Overview Traumatic Brain Injury (TBI) is a disruption in the brain’s normal functioning caused by physical impact to the head, such as a blow, bump, or jolt, or when an object penetrates the skull and enters the brain tissue. Clinical signs indicating an alteration in normal brain function include loss of consciousness or decreased consciousness, memory loss (amnesia) for events before or aft...